Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey

Huang, Rui,Rao, Huiying,Lv, Fangfang,Nan, Yuemin,Ren, Wanhua,Huang, Yan,Li, Jun,Tang, Hong,Huang, Yuan,Chalasani, Naga,Wei, Lai

DOI: https://doi.org/10.1007/s43441-022-00380-6

2022-01-01

Therapeutic Innovation & Regulatory Science

Abstract:Many new therapies of non-alcoholic fatty liver disease are being evaluated in clinical trials (CTs), but few of these trials involved sites in China. We evaluated influencing factors of Chinese patients’ perspectives in participation in CTs of non-alcoholic fatty liver disease. A questionnaire was designed to be completed by patients with non-alcoholic fatty liver disease at eight affiliated hospitals across China. 428 patients were included in this analysis, 63% were male and median age was 37.9 years (30.0–44.0). 54% patients rated “to help others” and 30% “to improve my health status” as the greatest benefit from CTs. The most important concerns were safety (43%) and patients’ benefit (26%). Improving liver fibrosis or cirrhosis (53%) and reducing fat in liver (21%) were desired efficacy of new drugs. Possibility of being treated with a placebo for up to 2–6 years played an influential (21%) or very influential (73%) role on participation. Lower education level, lower body mass index, and cirrhosis were positively associated with acceptance of liver biopsies. Anxiety of adverse effects of the new drug and requirement of 2–3 liver biopsies were negatively associated with patients’ attitudes toward participating in the trial. More than one-third of Chinese patients with NAFLD in this survey are willing to participate in CTs of NASH. For CTs of NASH treatment, potential effects on reversing fibrosis or cirrhosis would positively influence, while adverse effects of the new drug and requirement of multiple liver biopsies would negatively influence participation in our study.